Skip to main content
TipRanks
Go Ultimate75% OFF

Healthy Extracts (HYEX) AI Stock Analysis

8 Followers
HYEX

Healthy Extracts

(Other OTC:HYEX)

Select Model
Rating:53Neutral
Price Target:$1.50â–²(11.03% Upside)
Action:reiterated
Date:11/20/26

The score reflects a high-risk turnaround situation. Positive cash flow and bullish technical momentum are the primary strengths, but they are significantly counterbalanced by persistent net losses, a negative P/E, and recent corporate governance uncertainty following a board resignation.

Positive Factors
Healthy Gross MarginsSustained healthy gross margins indicate that HYEX’s products retain meaningful gross profitability before operating costs. This provides a foundation for future earnings improvement if the company can control expenses, increase scale, and convert product-level economics into durable operating profits.
Negative Factors
Persistent Operating LossesPersistent losses show that healthy product-level margins have not yet translated into sustainable company-wide profitability. Continued negative EBIT, EBITDA, and net income can consume capital, restrict reinvestment, and increase reliance on financing unless operating expenses and scale economics improve.

Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%HYEX-32.45%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$19.92M
Dividend Yield
―
Average Volume (3M)
720
Price to Earnings (P/E)
-9.1
Beta (1Y)
2.51
Revenue Growth
66.93%
EPS Growth
54.88%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Healthy Extracts Business Overview & Revenue Model

Company Description

Healthy Extracts Inc., through its various divisions, specializes in the global and domestic research, development, and sale of natural botanical products. Its portfolio encompasses dietary supplements crafted for cardiovascular wellness, alongside K...

Healthy Extracts Financial Statement Overview

Summary

Mixed financials: strong cash flow (Score 70) and improved balance sheet (Score 60) are offset by deeply unprofitable operations (Income Score 35). The company is a turnaround story with positive cash generation but no clear path to net profitability.

Income Statement

35Negative

Balance Sheet

60Neutral

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue5.99M4.51M3.11M2.49M2.25M1.47M
Gross Profit3.74M2.42M1.91M1.62M1.37M695.08K
EBITDA-1.27M-791.66K-183.15K-2.24M-910.71K-1.88M
Net Income-2.20M-881.12K-840.67K-2.47M-983.12K-1.99M
Balance Sheet
Total Assets32.14M27.82M2.38M2.64M2.78M3.03M
Cash, Cash Equivalents and Short-Term Investments143.27K146.94K112.02K19.44K65.65K222.10K
Total Debt9.13M2.64M941.90K1.13M593.52K342.62K
Total Liabilities10.93M3.80M1.97M1.68M902.79K558.84K
Stockholders Equity21.20M24.03M410.38K954.59K1.88M2.47M
Cash Flow
Free Cash Flow723.56K146.22K281.97K-415.75K-342.95K-997.30K
Operating Cash Flow723.56K165.52K281.97K-415.75K-334.96K-901.30K
Investing Cash Flow134.71K56.30K00-5,344-96.00K
Financing Cash Flow-904.45K-186.91K-189.39K369.54K239.52K1.16M

Healthy Extracts Technical Analysis

Technical Analysis SentimentPositive
Last Price1.35

Price Trends

50DMA1.15Positive
100DMA1.24Positive
200DMA1.60Negative

Market Momentum

MACD0.06Positive
RSI68.23Neutral
STOCH-2.04Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Positive. The current price of 1.35 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.15, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 68.23 is Neutral, neither overbought nor oversold. The STOCH value of -2.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYEX.

Healthy Extracts Risk Analysis

Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price.Q4, 2023
2.We have broad discretion in the use of our cash, and may not use it effectively.Q4, 2023

Healthy Extracts Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HYEX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RMTIRMTI56Neutral$24.86M-4.23-16.04%―-3.96%7.97%
AYTUAYTU55Neutral$28.91M-1.49-69.19%―-8.12%7.24%
CPIXCPIX55Neutral$94.47M1.37202.58%22.00%-39.11%-241.27%
HYEXHYEX53Neutral$19.92M-9.07-9.59%―66.93%54.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SCYXSCYX45Neutral$25.93M-2.23-18.65%―543.96%72.49%
COSMCOSM38Underperform$14.44M-0.22-118.89%―33.82%34.05%

* Healthcare Sector Average

Performance Comparison

0%200%400%HYEXRMTISCYXAYTUCPIXCOSMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HYEX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HYEXHealthy Extracts Inc1.35-0.67-33.12%
RMTIRockwell Medical6.26-2.65-29.77%
SCYXSCYNEXIS Inc2.60-2.84-52.11%
AYTUAytu BioScience2.660.6532.34%
CPIXCumberland Pharmaceuticals Inc.6.304.76309.36%
COSMCosmos Holdings 2.87-10.68-78.82%

Healthy Extracts Corporate Events

Private Placements and Financing

Healthy Extracts Enters Secured Convertible Note Financing Agreement

Neutral
Nov 17, 2026

On November 10, 2026, the company entered into a securities purchase agreement and issued HINTERLAND PARTNERS LLC a secured promissory note with a $555,556 principal amount, a $55,556 original issue discount, a 30-month maturity and 13% annual intere...

Executive/Board Changes

Healthy Extracts Announces Board Change After Director Resignation

Negative
Sep 18, 2026

Healthy Extracts, operating in the broader health and wellness sector, is overseen by a board of directors responsible for guiding its corporate governance and strategic direction. The company relies on its board committees to manage oversight functi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026